96803 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses; RNA viruses; Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus; Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV HIV-1 ; HIV-2
Sub-classes:CELL-PENETRATING PEPTIDES COMPRISING MULTIPLE 5-MER ALPHA-HELIX FRAGMENTS AND USES THEREOF
#2Oncolytic viruses targeting STAT3
#3ARC-BASED CAPSIDS AND USES THEREOF
#4METHOD OF ASSEMBLYING TWO-COMPONENT VIRUS-LIKE PARTICLE
#5CELL PENETRATING PEPTIDE FUNCTIONALIZED PERFLUOROCARBON NANOEMULSION COMPOSITIONS AND METHODS FOR IMAGING CELL POPULATIONS
#6Chloride salt of TAT-NR2B9C
#7ONCOLYTIC VIRUSES TARGETING STAT3
#8ONCOLYTIC VIRUSES TARGETING STAT3
#9Chimeric molecules and uses thereof
#10LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER
#11Protein-based purification matrices and methods of using the same
#12HIV vaccine formulation
#13PROPHYLACTIC PROTECTION AGAINST VIRAL INFECTIONS, PARTICULARLY HIV
#14ALLOGENEIC T-CELL-BASED HIV VACCINE TO INDUCE CELLULAR AND HUMORAL IMMUNITY
#15COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#16Chloride salt of TAT-NR2B9C
#17Gene expression inhibitors
#18Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells
#19Compositions and methods for inhibition of the lncRNA SAF to drive apoptotic cell death in human immunodeficiency virus (HIV) infected human macrophages
#20Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits
#21Chimeric molecules and uses thereof
#22Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
#23LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER
#24HIV vaccine formulation
#25Chloride salt of TAT-NR2B9c
#26Oncolytic viruses targeting STAT3
#27HIV peptide vaults and methods of making and using thereof
#28Recombinant HCMV and RHCMV vectors and uses thereof
#29Compositions and Methods for Evaluating Viral Receptor/Co-Receptor Usage and Inhibitors of Virus Entry Using Recombinant Virus Assays
#30METHODS FOR SAFE INDUCTION OF CROSS-CLADE IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN
#31Vaccines with interleukin-33 as an adjuvant
#32REPLICATIVE VACCINIA VIRUS VECTOR HIV VACCINE
#33Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
#34Constructs for continuous monitoring of live cells
#35HIV vaccine formulation
#36Prophylactic protection against viral infections, particularly HIV
#37ENDOSOMAL ESCAPE DOMAINS FOR DELIVERY OF MACROMOLECULES INTO CELLS
#38Chloride salt of TAT-NR2B9c
#39Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
#40Vaccines with interleukin-33 as an adjuvant
#41Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
#42Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
#43Recombinant HCMV and RHCMV vectors and uses thereof
#44PEPTIDE FOR SUPPRESSING AND TREATING OBESITY
#45TARGETING COMPOUNDS
#46B-cell stimulating fusion proteins of an antigen with BAFF or APRIL
#47Recombinant HCMV and RHCMV vectors and uses thereof
#48LATENT HUMAN IMMUNODEFICIENCY VIRUS REACTIVIATION
#49Process for the production of biologically active HIV-1 tat protein
#50Human immunodeficiency virus and uses thereof
#51T-cell immunogens derived from anti-viral proteins and methods of using same
#52Methods for determining the presence of antibodies blocking viral infection
#53Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
#54Tat complexes, and vaccines comprising them